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❚ Evidence summary
Acne vulgaris is the most common cuta-
neous disorder, affecting about 45 million
people in the United States. Five to 6 
million acne-related visits are made to
physicians in outpatient offices each year.1
For mild noninflammatory (come-
donal) acne, the preferred option is
monotherapy with topical retinoids.
Randomized controlled trials (RCTs) have
proven the efficacy of tretinoin, an older
retinoid for comedonal acne.2 In one RCT,
patients were randomly assigned to 1 of 3
treatment groups, each having 33
enrollees: patients in the first group
received 0.1% tazarotene gel as twice daily
application; the second group received
0.1% tazarotene gel in the evening and
vehicle gel in the morning; the third group
received vehicle gel twice daily. By 12
weeks, the first and second groups
achieved significantly greater improvement
in acne than the third group, based on
mean percentage reduction in noninflam-
matory lesions (46% and 41% vs 2%;
P=.002) and inflammatory lesions (38%
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What is the best treatment 
for mild to moderate acne?
For mild comedonal acne, monotherapy
with topical retinoids is the treatment of
choice (strength of recommendation 
[SOR]: A). For moderate comedonal and
mild to moderate papulopustular acne,
combination therapy with either benzoyl
peroxide or topical retinoids (adapalene
[Differin], tazarotene [Tazorac], tretinoin
[Retin-A]) plus topical antibiotics 
(erythromycin or clindamycin) is proven
most effective (SOR: A). Six to eight 
weeks should be allowed for most 
treatments to work before altering the 
regimen (SOR: A).
E V I D E N C E - B A S E D A N SW E R
Get patients (or parents) to agree to an
adequate trial before declaring failure 
Fortunately, we have excellent first-line 
therapies for mild to moderate acne. A
greater challenge is getting patients (or par-
ents) to agree to an adequate trial of these
agents, and then sharing objective data on
progress before hastily declaring failure.
We must remember the significant 
psychosocial impact that “zits” have on our
adolescent patients. Validating this central
concern and providing lay education on
acne pathophysiology help get patients to
agree to 6 weeks of therapy before judging
the effectiveness of treatment. Comparative
digital photographs and repeat counts of
inflammatory lesions and comedones at the
follow-up visit help significantly in objective
progress assessment and fostering 
therapeutic adherence.
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and 34% vs 9%; P=.01).3 Another 12-
week RCT of 237 patients with mild to
moderate acne demonstrated superior effi-
cacy with 0.1% adapalene cream over
placebo (P<.05).4 While most studies did
not compare the use of one retinoid vs
another, a recent meta-analysis of placebo-
controlled trials concluded that topical
tazarotene is more effective in treating
mild comedonal acne than adapalene or
tretinoin, although it may be more likely to
cause skin irritation.6,7
A systematic review evaluating the evi-
dence for treatment of acne found that
combining topical antibiotics with topical
retinoids or benzoyl peroxide is effective
for moderate noninflammatory (come-
donal) and mild to moderate inflamma-
tory (papulopustular) acne.7 Because of 
its antibacterial and anti-comedogenic
properties, benzoyl peroxide is preferred 
to retinoids for inflammatory acne.
Another benefit of using benzoyl peroxide
with antibiotic cream is its potential to
reduce antibiotic-associated resistance to
Propionibacterium acnes.7,8
No comparative trials or meta-analy-
ses compare efficacy of different combina-
tion therapies. A recent narrative review of
clinical trials concluded that clindamycin
plus benzoyl peroxide was more effective
in reducing inflammatory lesions than
monotherapy with either agent alone, and
was similar in efficacy to benzoyl perox-
ide/erythromycin combination.8 Similarly,
combination therapy with clindamycin
and adapalene was superior to clin-
damycin alone in improving mild to mod-
erate acne.9 Both 1% clindamycin and 2%
erythromycin were comparable in reduc-
ing inflammatory and noninflammatory
lesions for patients with moderate acne.10
Studies are ongoing for topical tetra-
cycline, topical isotretinoin, and light and
laser therapy in treatment of mild to 
moderate acne. 
Recommendations from others
An expert review stated that treatment of
acne should be individualized for best
results.7 A report from the Global Alliance
to Improve Outcomes in Acne states that
topical retinoids are appropriate first-line
therapy for all forms of acne and should be
combined with topical antimicrobial thera-
py when inflammatory lesions are present.11
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Comparing photos
and counting
lesions and 
comedones at the
follow-up visit help
patients stick 
to their therapy 
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